Du verden for et spennende selskap. Utdrag fra årsrapporten 2020
Synthetic Biology
«Synthetic Biology - a multidisciplinary area engaged in creating new biological parts, devices, systems, and DNA based therapeutics. ArcticZymes ligases (prototypes) and polymerases show great promise for future utility in this market.»
MarketsandMarkets™ Strategic Insights:
Synthetic Biology Market worth $30.7 billion by 2026
USD 9.5 billion in 2021
Liquid Biopsies
«Liquid Biopsies – DNA or other diagnostics tests are performed on blood or other body fluids. Unlike traditional invasive biopsies, liquid biopsies require a whole new set of molecular techniques to overcome the challenges of isolating very small amounts of DNA and amplifying it sufficiently to allow diagnosis. ArcticZymes´ proteinase, DNases, and SAN enzymes are already supporting customer efforts in developing such technologies»
Alliedmarketresearch:
The global liquid biopsy market size accounted for $1,204.2 million in 2020, and is estimated to reach $6,804.9 million by 2028, registering a CAGR of 20.9% from 2021 to 2028.
«Therapeutics – Gene Therapy
ArcticZymes´ business towards serving manufacturers of viral-based gene therapies and vaccines is a relatively new business. All our customers are still in the early stages of their development programs»
Fortune Business Insights:
The report further mentions that the market size was USD 3.61 billion in 2019 and is projected to reach USD 35.67 billion by 2027, exhibiting a CAGR of 33.6% during the forecast period”
«Synthetic Biology - a multidisciplinary area engaged in creating new biological parts, devices, systems, and DNA based therapeutics. ArcticZymes ligases (prototypes) and polymerases show great promise for future utility in this market.»
MarketsandMarkets™ Strategic Insights:
Synthetic Biology Market worth $30.7 billion by 2026
USD 9.5 billion in 2021
Liquid Biopsies
«Liquid Biopsies – DNA or other diagnostics tests are performed on blood or other body fluids. Unlike traditional invasive biopsies, liquid biopsies require a whole new set of molecular techniques to overcome the challenges of isolating very small amounts of DNA and amplifying it sufficiently to allow diagnosis. ArcticZymes´ proteinase, DNases, and SAN enzymes are already supporting customer efforts in developing such technologies»
Alliedmarketresearch:
The global liquid biopsy market size accounted for $1,204.2 million in 2020, and is estimated to reach $6,804.9 million by 2028, registering a CAGR of 20.9% from 2021 to 2028.
«Therapeutics – Gene Therapy
ArcticZymes´ business towards serving manufacturers of viral-based gene therapies and vaccines is a relatively new business. All our customers are still in the early stages of their development programs»
Fortune Business Insights:
The report further mentions that the market size was USD 3.61 billion in 2019 and is projected to reach USD 35.67 billion by 2027, exhibiting a CAGR of 33.6% during the forecast period”
Zleep
03.06.2021 kl 10:20
929
Tåler vel en gentagelse, da den hænger sammen med ovenstående NGS
ArcticZymes has entered into an agreement with Simcere Diagnostics to supply its HL-SAN product for Simcere's metagenomics sequencing tests
Simcere Diagnostics Utilizing state-of-the-art technology platforms including Next Generation Sequencing
https://newsweb.oslobors.no/message/515159
https://www.illumina.com/company/news-center/feature-articles/a-golden-age-for-chinas-ngs-industry.html
ArcticZymes has entered into an agreement with Simcere Diagnostics to supply its HL-SAN product for Simcere's metagenomics sequencing tests
Simcere Diagnostics Utilizing state-of-the-art technology platforms including Next Generation Sequencing
https://newsweb.oslobors.no/message/515159
https://www.illumina.com/company/news-center/feature-articles/a-golden-age-for-chinas-ngs-industry.html
Redigert 03.06.2021 kl 10:29
Du må logge inn for å svare
Zleep
03.06.2021 kl 08:59
1044
FDA godkendte deres første Synthetic Biology test i november 2020. Testen er baseret på NGS teknologien Next generation Seqencing.
"ARK Invest forecasts that clinical adoption of next generation DNA sequencing (NGS) will drive volumes from ~2.6 million in 2019 to more than 100 million in 2024"
De 10 største virksomheder der beskæftiger sig med NGS teknologien
Illumina. .
Thermo Fisher Scientific
BGI Genomics
Agilent Technologies.
10X Genomics
GENEWIZ
QIAGEN
MACROGEN
Pacific Biosciences of California
Oxford Nanopore Technologies
Illumina er markedsleder og levere selve laboratorie udstyret til teknologien. ArcticZymes levere enzymer til alle ovenstående virksomheder formoder jeg
https://www.fda.gov/drugs/fda-approves-liquid-biopsy-ngs-companion-diagnostic-test-multiple-cancers-and-biomarkers
"ARK Invest forecasts that clinical adoption of next generation DNA sequencing (NGS) will drive volumes from ~2.6 million in 2019 to more than 100 million in 2024"
De 10 største virksomheder der beskæftiger sig med NGS teknologien
Illumina. .
Thermo Fisher Scientific
BGI Genomics
Agilent Technologies.
10X Genomics
GENEWIZ
QIAGEN
MACROGEN
Pacific Biosciences of California
Oxford Nanopore Technologies
Illumina er markedsleder og levere selve laboratorie udstyret til teknologien. ArcticZymes levere enzymer til alle ovenstående virksomheder formoder jeg
https://www.fda.gov/drugs/fda-approves-liquid-biopsy-ngs-companion-diagnostic-test-multiple-cancers-and-biomarkers
Redigert 03.06.2021 kl 09:04
Du må logge inn for å svare
JosefK
03.06.2021 kl 06:50
1209
Det er bare å lese. Les gjerne årsrapporter 10-15 år tilbake i tid og prøv å forstå hvordan satsingen innen PCR og senere SAN har formet selskapet.
rufus01
03.06.2021 kl 00:59
1307
Ja her er det bare og benke seg til og være litt tålmodig, i perioder som nå når aksjen virker og være ganske så volatil. Markedet AZT operer i spås en eksponensiell vekst i årene som kommer. Produktene er i verdensklasse, og alt ligger til rette for at AZT vil bli med på denne eksponensielle veksten.